HIF-1α as a Potential Target for Pharmacologic Correction after Prenatal Hypoxia

first_page Download PDF settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open AccessAbstract HIF-1α as a Potential Target for Pharmacologic Correction after Prenatal Hypoxia † by Olena Gennadiivna AliyevaOlena Gennadiivna Aliyeva SciProfiles Scilit Preprints.org Google Scholar 1,*, Igor Fedorovich BelenichevIgor Fedorovich Belenichev SciProfiles Scilit Preprints.org Google Scholar 2 and Olena Olexandrivna PopazovaOlena Olexandrivna Popazova SciProfiles Scilit Preprints.org Google Scholar 2 1 Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia 69035, Ukraine 2 Department of Histology, Cytology and Embryology, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia 69035, Ukraine * Author to whom correspondence should be addressed. † Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: https://sciforum.net/event/IECBM2024. Proceedings 2024, 103(1), 55; https://doi.org/10.3390/proceedings2024103055 Published: 12 April 2024 (This article belongs to the Proceedings of The 3rd International Electronic Conference on Biomolecules) Download keyboard_arrow_down Download PDF Download PDF with Cover Download XML Download Epub Versions Notes Keywords: CNS; prenatal hypoxia; endogenous neuroprotection; HIF-1α Chronic prenatal hypoxia (CPH) is one of the most common causes of neonatal mortality and postnatal disorders of the nervous system and the mental development of infants. The search for new methods to treat the effects of CPH is a high-priority problem of modern pharmacology. HIF-1α in hypoxic conditions activates mechanisms of endogenous neuroprotection and can be used as a target for pharmacological correction.Aim of the work: To study the possibilities of the HIF-1α-modulating effects of different pharmacological agents in the model of CPH.CPH was modeled by administering sodium nitrite (50 mg/kg) to pregnant female white rats from day 16 of gestation. The offspring were treated with the following drugs: piracetam, thiotriazoline, nikomex, tamoxifen, cerebrocurin, angiolin, glutoredoxin, l-arginine, and HSF-1 during the first 30 days of life. The concentration of HIF-1α in the plasma and brain homogenate of rats at 30 and 60 days of life was determined using the enzyme-linked immunosorbent assay.It was found that CPH leads to a decrease in the concentration of HIF-1α in the nervous tissue of the brain and blood plasma. Drug administration results in a significant increase in the content of HIF-1α in the studied objects immediately at the end of treatment with continued positive effects on the 60th day of life. The maximum effect was demonstrated on day 30 by cerebrocurin, angiolin, and HSF1, and on day 60 by cerebrocurin, angiolin, and thiatriazolin.Our research provides evidence that the medications being tested are an effective way to modulate HIF-1α and may be a new alternative for the treatment and prevention of nervous system disorders in children caused by CPH. Author ContributionsConceptualization, methodology, I.F.B. and O.G.A.; conducting an experiment, O.G.A. and O.O.P.; data curation, O.O.P.; writing—original draft preparation, O.G.A.; software, O.G.A.; supervision, project administration, I.F.B. All authors have read and agreed to the published version of the manuscript.FundingThis research received no external funding.Institutional Review Board StatementThe experimental studies were carried out in accordance with the "Regulations on the Use of Animals in Biomedical Research" and with the European Convention on the Protection of Animals Used for Scientific and Other Purposes. The experiment was approved by the Bioethics Committee of Zaporizhzhia State Medical and Pharmaceutical University.Informed Consent StatementNot applicable.Data Availability StatementThe data are available from the corresponding author upon reasonable request.Conflicts of InterestThe authors declare no conflict of interest.Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Share and Cite MDPI and ACS Style Aliyeva, O.G.; Belenichev, I.F.; Popazova, O.O. HIF-1α as a Potential Target for Pharmacologic Correction after Prenatal Hypoxia. Proceedings 2024, 103, 55. https://doi.org/10.3390/proceedings2024103055 AMA Style Aliyeva OG, Belenichev IF, Popazova OO. HIF-1α as a Potential Target for Pharmacologic Correction after Prenatal Hypoxia. Proceedings. 2024; 103(1):55. https://doi.org/10.3390/proceedings2024103055 Chicago/Turabian Style Aliyeva, Olena Gennadiivna, Igor Fedorovich Belenichev, and Olena Olexandrivna Popazova. 2024. "HIF-1α as a Potential Target for Pharmacologic Correction after Prenatal Hypoxia" Proceedings 103, no. 1: 55. https://doi.org/10.3390/proceedings2024103055 Article Metrics No No Article Access Statistics Multiple requests from the same IP address are counted as one view.